Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
DARE Dare Bioscience	$2.02 -1.0%	$2.41	$1.83 ▼ $9.19	$27.23M	1.11	608,164 shs	96,171 shs
MBRX Moleculin Biotech	$0.61 +11.3%	$0.56	$0.25 ▼ $3.65	$18.40M	1.39	4.56 million shs	37.85 million shs
PMN Promis Neurosciences	$0.53 -2.8%	$0.59	$0.38 ▼ $1.59	$27.63M	-0.04	2.74 million shs	236,135 shs
PRFX PainReform	$1.61 -1.2%	$1.48	$1.25 ▼ $16.63	$3.24M	0.57	2.04 million shs	242,188 shs

10 Best Stocks to Own: Fall 2025

Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Fall 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
DARE Dare Bioscience	-1.92%	+0.99%	-20.62%	-28.92%	-42.05%
MBRX Moleculin Biotech	-5.10%	-8.49%	-3.79%	-38.85%	-78.61%
PMN Promis Neurosciences	+2.69%	-2.83%	-44.35%	+14.38%	-56.43%
PRFX PainReform	-6.32%	-31.22%	+9.40%	-16.41%	+50.04%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
DARE Dare Bioscience	2.4718 of 5 stars	3.5	5.0	2.6	0.0	0.0
MBRX Moleculin Biotech	2.7272 of 5 stars	3.5	4.0	1.5	1.7	0.6
PMN Promis Neurosciences	3.2507 of 5 stars	3.5	5.0	3.3	0.8	0.6
PRFX PainReform	1.2903 of 5 stars	0.0	4.0	2.7	1.7	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
DARE Dare Bioscience	3.00	Buy	$12.00	494.06% Upside
MBRX Moleculin Biotech	3.00	Buy	$4.00	558.65% Upside
PMN Promis Neurosciences	3.00	Buy	$4.33	712.40% Upside
PRFX PainReform	2.00	Hold	N/A	N/A

Current Analyst Ratings Breakdown

Latest PRFX, PMN, DARE, and MBRX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/27/2025	MBRX Moleculin Biotech	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$4.00
7/21/2025	PMN Promis Neurosciences	Leede Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Moderate Buy
7/14/2025	PMN Promis Neurosciences	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$4.00
7/14/2025	PMN Promis Neurosciences	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$4.00
6/18/2025	MBRX Moleculin Biotech	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$4.00
6/9/2025	MBRX Moleculin Biotech	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Buy	$4.00

(Data available from 8/27/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
DARE Dare Bioscience	$10K	2,722.96	N/A	N/A	($0.94) per share	-2.15
MBRX Moleculin Biotech	N/A	N/A	N/A	N/A	($0.24) per share	N/A
PMN Promis Neurosciences	N/A	N/A	N/A	N/A	($0.01) per share	N/A
PRFX PainReform	N/A	N/A	N/A	N/A	$2.08 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
DARE Dare Bioscience	-$4.05M	-$2.14	N/A	N/A	N/A	N/A	N/A	-103.70%	11/13/2025 (Estimated)
MBRX Moleculin Biotech	-$21.76M	N/A	0.00	N/A	N/A	N/A	-1,498.41%	-114.47%	11/14/2025 (Estimated)
PMN Promis Neurosciences	$2.78M	-$0.21	N/A	N/A	N/A	N/A	-266.69%	-131.59%	11/13/2025 (Estimated)
PRFX PainReform	-$14.59M	-$147.33	N/A	∞	N/A	N/A	N/A	N/A	8/28/2025 (Estimated)

Latest PRFX, PMN, DARE, and MBRX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2025	Q2 2025	DARE Dare Bioscience	-$0.55	-$0.45	+$0.10	-$0.45	$0.14 million	($0.02) million
8/13/2025	Q2 2025	PMN Promis Neurosciences	-$0.22	-$0.29	-$0.07	-$0.29	N/A	N/A
8/12/2025	Q2 2025	MBRX Moleculin Biotech	-$0.39	-$0.49	-$0.10	-$0.49	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
DARE Dare Bioscience	N/A	N/A	N/A	N/A	N/A
MBRX Moleculin Biotech	N/A	N/A	N/A	N/A	N/A
PMN Promis Neurosciences	N/A	N/A	N/A	N/A	N/A
PRFX PainReform	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
DARE Dare Bioscience	N/A	0.34	0.34
MBRX Moleculin Biotech	N/A	1.15	1.15
PMN Promis Neurosciences	N/A	0.97	0.97
PRFX PainReform	N/A	1.81	1.81

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
DARE Dare Bioscience	6.70%
MBRX Moleculin Biotech	15.52%
PMN Promis Neurosciences	50.13%
PRFX PainReform	37.28%

Insider Ownership

Company	Insider Ownership
DARE Dare Bioscience	4.80%
MBRX Moleculin Biotech	2.10%
PMN Promis Neurosciences	6.11%
PRFX PainReform	34.40%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
DARE Dare Bioscience	30	13.48 million	12.83 million	Not Optionable
MBRX Moleculin Biotech	20	30.29 million	29.65 million	Not Optionable
PMN Promis Neurosciences	5	51.81 million	48.64 million	Not Optionable
PRFX PainReform	4	2.01 million	1.32 million	Not Optionable

PRFX, PMN, DARE, and MBRX Headlines

Recent News About These Companies

PainReform’s DeepSolar accepted into Nvidia Connect Program

August 19, 2025 | msn.com

PainReform’s DeepSolar Joins NVIDIA Connect Program to Enhance Solar Forecasting

August 19, 2025 | msn.com

Nvidia enrollment sends this stock soaring 130%

August 19, 2025 | finbold.comF

Top Stocks To Watch: IOVA Soars On Regulatory Approval, FDA Fast Tracks Aldeyra's Drug

August 19, 2025 | rttnews.com

PainReform Ltd.'s DeepSolar Enters NVIDIA Connect Program to Enhance AI-Driven Solar Forecasting Solutions

August 19, 2025 | quiverquant.comQ

PainReform/DeepSolar Accepted into NVIDIA Connect Program

August 19, 2025 | globenewswire.com

PainReform Enters Cataract Surgery Market with LayerBio Investment

August 14, 2025 | msn.com

PainReform Ltd. Completes Strategic Investment in LayerBio to Enter $9B Global Cataract Surgery Market with Breakthrough Non-Opiate, Non-Steroidal Postoperative NSAID Drug ...

August 13, 2025 | uk.finance.yahoo.com

PainReform completes strategic investment in LayerBio

August 13, 2025 | msn.com

PainReform Ltd. Completes Strategic Investment in LayerBio to Enter $9B Global Cataract Surgery Market with Breakthrough Non-Opiate, Non-Steroidal Postoperative NSAID Drug Delivery System

August 13, 2025 | globenewswire.com

Painreform stock falls after announcing strategic investment in ...

July 11, 2025 | investing.com

PainReform invests in LayerBio to expand into ophthalmology

July 11, 2025 | investing.com

PainReform Ltd. enters into a Strategic Investment Agreement to Expand ...

July 11, 2025 | seekingalpha.com

Painreform stock falls after announcing strategic investment in LayerBio

July 10, 2025 | au.investing.com

Painreform Shares Drop 11% After Revealing Strategic Stake in LayerBio

July 10, 2025 | msn.com

PainReform Expands into Ophthalmology with Strategic Investment in LayerBio

July 10, 2025 | tipranks.com

PainReform Ltd. enters into a Strategic Investment Agreement to Expand its Non-Opiate Pain ...

July 10, 2025 | gurufocus.com

PainReform Ltd. enters into a Strategic Investment Agreement to Expand its Non-Opiate Pain ...

July 10, 2025 | gurufocus.com

PainReform Ltd. enters into a Strategic Investment Agreement to Expand its Non-Opiate Pain Management Pipeline into Opthamology with LayerBio

July 10, 2025 | globenewswire.com

Blade Ranger: Consideration from PainReform Transaction Continues to Mature Following Growth in Software Sales

May 27, 2025 | prnewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

PRFX, PMN, DARE, and MBRX Company Descriptions

Dare Bioscience NASDAQ:DARE

$2.02 -0.02 (-0.98%)

Closing price 04:00 PM Eastern

Extended Trading

$2.04 +0.02 (+0.74%)

As of 05:45 PM Eastern

Daré Bioscience, Inc., a biopharmaceutical company, identifies, develops, and markets products for women's health in the United States. It develops therapies in the areas of contraception, reproductive health, menopause, fertility, and sexual and vaginal health. The company offers XACIATO for the treatment of bacterial vaginosis in female patients 12 years of age and older. It is developing Ovaprene, a hormone-free, monthly intravaginal contraceptive; Sildenafil Cream, a cream formulation of sildenafil for topical administration to the female genitalia on demand for the treatment of female sexual arousal disorder; DARE-HRT1 to treat moderate to-severe vasomotor symptoms in menopausal hormone therapy; DARE-VVA1 for the treatment of moderate-to-severe dyspareunia or pain during sexual intercourse; and DARE-CIN to treat cervical intraepithelial neoplasia and other human papillomavirus related pathologies. The company is also developing DARE-PDM1 for the treatment of primary dysmenorrhea; DARE-204 and DARE-214, an injectable formulations contraception of etonogestrel designed to provide contraception over 6-month and 12-month periods; DARE-FRT1, an intravaginal ring designed to deliver bio-identical progesterone for luteal phase support as part of an in vitro fertilization treatment plan; and DARE-PTB1 for the prevention of preterm birth. In addition, it is developing DARE-LARC1, a contraceptive implant delivering levonorgestrel with a woman-centered design that controlled contraceptive option; DARE-LBT, a novel hydrogel formulation for vaginal delivery of live biotherapeutics to support vaginal health; DARE-GML, a multi-target antimicrobial agent; DARE-RH1, a novel approach to non-hormonal contraception for men and women by targeting the CatSper ion channel; and DARE-PTB2 for the prevention and treatment of idiopathic preterm birth through inhibition of a stress response protein. Daré Bioscience, Inc. is headquartered in San Diego, California.

Moleculin Biotech NASDAQ:MBRX

$0.61 +0.06 (+11.33%)

Closing price 04:00 PM Eastern

Extended Trading

$0.60 -0.01 (-2.03%)

As of 05:55 PM Eastern

Moleculin Biotech, Inc., a clinical stage pharmaceutical company, focuses on the development of drug candidates for the treatment of cancers and viruses. Its lead drug candidate is Annamycin, which is in Phase 1B/2 clinical trials for the treatment of relapsed or refractory acute myeloid leukemia (AML) and soft tissue sarcoma metastasized to the lungs. The company is also developing WP1066, an immune/transcription modulator designed to inhibit phosphorylated signal transducer and activator of transcription and other oncogenic transcription factors targeting brain tumors, and pancreatic and other cancers. In addition, it develops WP1220, an analog of WP1066 for the topical treatment of cutaneous T-cell lymphoma; and WP1122 to treat viruses, as well as cancer indications, including brain tumors, and pancreatic and other cancers. The company was incorporated in 2015 and is headquartered in Houston, Texas.

Promis Neurosciences NASDAQ:PMN

$0.53 -0.02 (-2.84%)

Closing price 03:55 PM Eastern

Extended Trading

$0.53 0.00 (-0.07%)

As of 05:17 PM Eastern

ProMIS Neurosciences, Inc. discovers and develops antibody therapies and therapeutic vaccines neurodegenerative diseases and other misfolded protein diseases in Canada. The company's proprietary discovery platform comprises ProMIS and Collective Coordinates algorithms to predict novel targets known as disease specific epitopes on the molecular surface of misfolded proteins. Its lead product candidates comprise of PMN310, a monoclonal antibody (mAb) for toxic oligomers in AD; PMN267, a TDP-43; and PMN442, a mAb targeting toxic a-syn oligomers and seeding fibrils. The company was formerly known as Amorfix Life Sciences Ltd. and changed its name to ProMIS Neurosciences, Inc. in July 2015. ProMIS Neurosciences, Inc. was incorporated in 2004 and is headquartered in Toronto, Canada.

PainReform NASDAQ:PRFX

$1.61 -0.02 (-1.23%)

Closing price 04:00 PM Eastern

Extended Trading

$1.56 -0.06 (-3.42%)

As of 05:52 PM Eastern

PainReform Ltd., a clinical stage specialty pharmaceutical company, focuses on the reformulation of established therapeutics and provides an extended period of post-surgical pain relief in Israel. It develops PRF-110, a viscous clear oil-based solution that is instilled directly into the surgical wound to provide localized and extended post-operative analgesia, as well as in Phase 3 clinical trial for pain treatment of patients undergoing bunionectomy and second trial for pain treatment of hernia repair operations. The company was incorporated in 2007 and is based in Tel Aviv, Israel.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time